$11.15
0.45% yesterday
NYSE, Jul 30, 10:00 pm CET
ISIN
US90240B1061
Symbol
TYRA

Tyra Bioscience Stock price

$11.15
+1.58 16.51% 1M
-3.56 24.20% 6M
-2.75 19.78% YTD
-10.42 48.31% 1Y
+1.26 12.74% 3Y
-14.85 57.12% 5Y
-14.85 57.12% 10Y
-14.85 57.12% 20Y
NYSE, Closing price Wed, Jul 30 2025
-0.05 0.45%
ISIN
US90240B1061
Symbol
TYRA
Industry

Key metrics

Basic
Market capitalization
$595.6m
Enterprise Value
$276.7m
Net debt
positive
Cash
$318.9m
Shares outstanding
53.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.8
Financial Health
Equity Ratio
94.4%
Return on Equity
-25.2%
ROCE
-34.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-113.2m | $-135.0m
EBIT
$-113.7m | $-142.4m
Net Income
$-96.4m | $-114.7m
Free Cash Flow
$-73.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-29.3% | -30.2%
EBIT
-29.3% | -36.7%
Net Income
-27.8% | -32.6%
Free Cash Flow
-16.7%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.6
FCF per Share
$-1.4
Short interest
16.7%
Employees
49
Rev per Employee
$0.0
Show more

Is Tyra Bioscience a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,020 stocks worldwide.

Tyra Bioscience Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Tyra Bioscience forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Tyra Bioscience forecast:

Buy
93%
Hold
7%

Financial data from Tyra Bioscience

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 26 26
39% 39%
-
- Research and Development Expense 88 88
27% 27%
-
-113 -113
29% 29%
-
- Depreciation and Amortization 0.54 0.54
35% 35%
-
EBIT (Operating Income) EBIT -114 -114
29% 29%
-
Net Profit -96 -96
28% 28%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tyra Bioscience directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tyra Bioscience Stock News

Neutral
PRNewsWire
9 days ago
CARLSBAD, Calif. , July 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that company management will participate in a virtual fireside chat as part of the UBS Biotech Management Live ...
Neutral
PRNewsWire
22 days ago
CARLSBAD, Calif. , July 8, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that a late-breaking abstract has been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO...
Neutral
PRNewsWire
about one month ago
-TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC- -Initial 3-month complete response (CR) data expected to be reported in 1H 2026- CARLSBAD, Calif. , June 30, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportuniti...
More Tyra Bioscience News

Company Profile

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.

Head office United States
CEO Todd Harris
Employees 49
Founded 2018
Website tyra.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today